Assembly Biosciences. has filed a patent for compounds with allosteric effector properties against Hepatitis B virus Cp. The patent also includes methods for treating viral infections like hepatitis B by administering the disclosed compounds to patients in need. GlobalData’s report on Assembly Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Assembly Biosciences, Cancer treatment biomarkers was a key innovation area identified from patents. Assembly Biosciences's grant share as of January 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
The filed patent (Publication Number: US20240025890A1) includes claims related to a compound represented by a specific formula, with specific compounds canceled and one compound (1553) specified. The patent also outlines a method for modifying a viral core protein by administering the compound mentioned in claim 22. This method involves affecting functions upstream of viral assembly, such as modulating cccDNA transcription, RNA stability, and protein-protein interaction within the viral assembly. Additionally, the method allows for the administration of other active compounds like entecavir, lamivudine, telbivudine, and more, with entecavir specifically mentioned as an option.
Furthermore, the patent describes another method for modifying a viral core protein by administering the compound mentioned in claim 29. Similar to the previous method, this approach also involves affecting functions upstream of viral assembly and modulating cccDNA transcription, RNA stability, and protein-protein interaction within the viral assembly. Additionally, this method allows for the administration of other active compounds like entecavir, lamivudine, telbivudine, and more, with entecavir specifically highlighted as a potential option. These methods outlined in the patent provide a novel approach to modifying viral core proteins and potentially impacting viral assembly processes, offering a new avenue for antiviral treatment strategies.
To know more about GlobalData’s detailed insights on Assembly Biosciences, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
